52 completed, 27 recruiting, 19 terminated, 11 active not recruiting. 125 Phase 1, 55 Phase 2.
Follow Mantle Cell Lymphoma: new trials by email Literature Review of Mantle Cell Lymphoma trials Research Report on Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len, Rituximab plus lenalidomide, Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len - Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 40 | 2026-07-10 | 2026-07-13 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 27 | 2025-05-29 | 2026-01-30 |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies Pirtobrutinib, LV20.19 CAR T cells - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2025-02-06 | 2026-08-06 |
| A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Sonrotoclax, Zanubrutinib - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 258 | 2025-01-23 | 2026-10-26 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
| Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma Zanubrutinib, Tafasitamab - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Alvaro Alencar, MD | 27 | 2024-05-03 | 2026-09-21 |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Recruiting | Stanford University | 148 | 2024-03-29 | 2026-08-12 |
| Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies autologous hematopoietic stem cells added to planned CAR T - Hematologic Malignancy, Large B-cell Lymphoma | Phase 1 | Recruiting | Joshua Sasine, MD, PhD | 20 | 2024-03-02 | 2026-08-10 |
| A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma Glofitamab, Obinutuzumab, Lenalidomide - Mantle Cell Lymphoma, MCL | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 39 | 2024-01-08 | 2026-03-27 |
| CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 24 | 2023-10-26 | 2026-10-09 |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. ONM-501, Cemiplimab - Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | OncoNano Medicine, Inc. | 168 | 2023-10-13 | 2025-12-24 |
| TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) 400mg of TQB3909 tablets, 600mg of TQB3909 tablets - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 19 | 2023-10-05 | 2025-12-30 |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas Tazemetostat Pill - Follicular Lymphoma, B-Cell Lymphoma | Phase 1 | Active not recruiting | Weill Medical College of Cornell University | 15 | 2023-10-04 | 2026-06-17 |
| IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas IKS03 - B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Iksuda Therapeutics Ltd. | 140 | 2023-09-05 | 2026-11-03 |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 50 | 2023-08-10 | 2026-10-26 |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2023-08-01 | 2026-02-23 |
Showing 20 of 125. Sign in to see all of them.
Lymphoma, Mantle-Cell (125) · Lymphoma, Follicular (65) · Lymphoma, Large B-Cell, Diffuse (56) · Leukemia, Lymphocytic, Chronic, B-Cell (52) · Lymphoma, B-Cell, Marginal Zone (48) · Lymphoma, Non-Hodgkin (41) · Lymphoma (25) · Lymphoma, B-Cell (23) · Waldenstrom Macroglobulinemia (18) · Burkitt Lymphoma (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Recurrence (10) · Hematologic Neoplasms (8) · Leukemia (8) · Leukemia, Myeloid, Acute (6)
Hemic and Lymphatic Diseases (125) · Immune System Diseases (124) · Immunoproliferative Disorders (124) · Lymphatic Diseases (124) · Neoplasms by Histologic Type (124) · Lymphoproliferative Disorders (123) · Neoplasms (119) · Lymphoma (100) · Lymphoma, Non-Hodgkin (84) · Hematologic Diseases (64) · Disease Attributes (58) · Pathologic Processes (58) · Pathological Conditions, Signs and Symptoms (58) · Lymphoma, B-Cell (57) · Leukemia, Lymphoid (54)
Rituximab (22) · Cyclophosphamide (13) · ibrutinib (13) · fludarabine (12) · Bendamustine Hydrochloride (10) · Lenalidomide (10) · Bortezomib (9) · venetoclax (8) · obinutuzumab (7) · Cytarabine (5) · fludarabine phosphate (5) · Vincristine (4) · Antigens, CD19 (3) · CT-P10 (3) · Carmustine (3)
M.D. Anderson Cancer Center (5) · BeOne Medicines (4) · Memorial Sloan Kettering Cancer Center (4) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4) · City of Hope Medical Center (3) · ADC Therapeutics S.A. (2) · Amgen (2) · Celldex Therapeutics (2) · Dana-Farber Cancer Institute (2) · Gilead Sciences (2) · Massachusetts General Hospital (2) · National Cancer Institute (NCI) (2) · TG Therapeutics, Inc. (2) · University of Michigan Rogel Cancer Center (2) · Weill Medical College of Cornell University (2)
United States (95) · China (19) · United Kingdom (12) · Australia (10) · France (10) · Italy (9) · Spain (9) · Germany (7) · Canada (5) · Japan (4) · Belgium (3) · Brazil (3) · Poland (3) · South Korea (3) · Sweden (3)
Jeremy Abramson, MD (2) · Ronald Levy (2) · Ajay Gopal (1) · Alex Herrera (1) · Alvaro Alencar, MD (1) · Amitkumar Mehta (1) · Anand Jillella, MD (1) · Andre Goy, MD (1) · Andrew Zelenetz, MD,PhD (1) · Anita Kumar, MD (1) · Arturo Molina, MD (1) · Austin I Kim, MD (1)
PMID 34398557, PMID 34515338, PMID 34780125, PMID 19238148, PMID 21816833, PMID 25145344, PMID 27354719, PMID 28054442, PMID 29296805, PMID 30082475, PMID 30558987, PMID 31110096, PMID 31120355, PMID 31723767, PMID 32126141, PMID 32380537, PMID 32502336, PMID 32537847, PMID 33181832, PMID 33236943, PMID 33558202, PMID 33676628, PMID 34196037, PMID 34615723, PMID 34840720, PMID 35135810, PMID 35595730, PMID 36180329, PMID 37013954, PMID 37078706, PMID 37192437, PMID 37407001, PMID 37481608, PMID 37562004, PMID 37624619, PMID 37781158, PMID 37930156, PMID 37939259, PMID 38319241, PMID 38861666, PMID 39033770, PMID 39192036, PMID 39415923, PMID 39737396, PMID 40845254, PMID 41055698, PMID 41544219, PMID 41980020, PMID 42069409, PMID 42216090
2018 (3), 2014 (2), P30CA016672 (2), P30CA033572 (2), R35CA197353 (2), 2015 (1), 2016 (1), 2019 (1), P01CA044991 (1), P30CA015704 (1), P30CA138292 (1), P50CA107399 (1), R01CA193140 (1), UL1TR002240 (1)